Find Golidocitinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 2091134-68-6, Azd-4205, Azd4205, Unii-3by9z3m34g, Jak1-in-3, 3by9z3m34g
Molecular Formula
C25H31N9O2
Molecular Weight
489.6  g/mol
InChI Key
CVCVOSPZEVINRM-MRXNPFEDSA-N
FDA UNII
3BY9Z3M34G

Golidocitinib
Golidocitinib is an orally available inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, golidocitinib inhibits JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types. Additionally, JAK1 may be a primary driver of STAT3 phosphorylation and signaling, which plays a role in neoplastic transformation, resistance to apoptosis, tumor angiogenesis, metastasis, immune evasion, and treatment resistance.
1 2D Structure

Golidocitinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2R)-N-[3-[2-[(3-methoxy-1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide
2.1.2 InChI
InChI=1S/C25H31N9O2/c1-16(34-12-10-32(2)11-13-34)23(35)28-20-7-5-6-17-18(14-27-22(17)20)19-8-9-26-25(29-19)30-21-15-33(3)31-24(21)36-4/h5-9,14-16,27H,10-13H2,1-4H3,(H,28,35)(H,26,29,30)/t16-/m1/s1
2.1.3 InChI Key
CVCVOSPZEVINRM-MRXNPFEDSA-N
2.1.4 Canonical SMILES
CC(C(=O)NC1=CC=CC2=C1NC=C2C3=NC(=NC=C3)NC4=CN(N=C4OC)C)N5CCN(CC5)C
2.1.5 Isomeric SMILES
C[C@H](C(=O)NC1=CC=CC2=C1NC=C2C3=NC(=NC=C3)NC4=CN(N=C4OC)C)N5CCN(CC5)C
2.2 Other Identifiers
2.2.1 UNII
3BY9Z3M34G
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 2091134-68-6

2. Azd-4205

3. Azd4205

4. Unii-3by9z3m34g

5. Jak1-in-3

6. 3by9z3m34g

7. (2r)-n-[3-[2-[(3-methoxy-1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-1h-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide

8. Golidocitinib [inn]

9. Chembl4577523

10. Schembl18662606

11. Gtpl10744

12. Bdbm264212

13. Ex-a2671

14. Example 32 [us9714236b2]

15. Nsc801813

16. Nsc-801813

17. Compound 21 [pmid: 32297743]

18. Ac-36748

19. Ba177711

20. Hy-107361

21. Cs-0028212

22. Us9714236, 32

23. (.alpha.r)-n-(3-(2-((3-methoxy-1-methyl-1h-pyrazol-4-yl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-.alpha.,4-dimethyl-1-piperazineacetamide

24. (2r)-n-(3-{2-[(3- Methoxy-1-methyl- 1h-pyrazol-4-yl)amino] Pyrimidin-4- Yl}-1h-indol-7-yl)-2-(4- Methylpiperazin-1- Yl)propanamide

25. 1-piperazineacetamide, N-(3-(2-((3-methoxy-1-methyl-1h-pyrazol-4-yl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-.alpha.,4-dimethyl-, (.alpha.r)-

26. 1-piperazineacetamide, N-(3-(2-((3-methoxy-1-methyl-1h-pyrazol-4-yl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-alpha,4-dimethyl-, (alphar)-

2.4 Create Date
2017-04-22
3 Chemical and Physical Properties
Molecular Weight 489.6 g/mol
Molecular Formula C25H31N9O2
XLogP31.9
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count8
Rotatable Bond Count7
Exact Mass489.26007127 g/mol
Monoisotopic Mass489.26007127 g/mol
Topological Polar Surface Area116 Ų
Heavy Atom Count36
Formal Charge0
Complexity736
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty